The evidence, reviewed frankly
What the published research on exosomes in aesthetics and hair actually consists of: study designs, sample sizes, control groups, funding, and the questions nobody has answered.
Published by Northbank Media. Last reviewed 2026-07-31. Information only. This site is not a clinic and gives no medical advice.
The published work on exosomes in aesthetics and hair is dominated by laboratory and animal studies. The human clinical literature is small in number, small in sample size, short in follow up and frequently connected to the companies supplying the preparations.
The deeper problem is comparability. Products described by the same word differ in source, purification, characterisation and dose, so a positive finding for one tells you very little about another. There is no reliable UK outcome data at all.
A treatment can be plausible and unproven at the same time. Those are not contradictory states, and confusing them is the most common error in this field. This page is about the second word.
The shape of the literature
If you search the scientific literature for exosomes and skin, or exosomes and hair, you will find a great deal of material. Most of it is not about the treatment you are being offered. It divides roughly as follows.
Laboratory studies make up the largest share. Cells are grown in culture, vesicles are added, and something is measured: collagen gene expression, fibroblast proliferation, dermal papilla cell activity, inflammatory markers. This work is real science and it is where the hypothesis comes from. It is also several steps removed from a person having a treatment. Cells in a dish sit in a controlled environment with the preparation applied directly to them at a concentration the experimenter chose. Skin does not work that way.
Animal studies come next. Mice are the usual model. These add whole organism biology and are a necessary step. In hair specifically they are also a weak model, because rodent hair cycling is synchronised and androgen driven pattern loss as it occurs in humans does not exist in a mouse.
Human studies are the smallest category and the only one that speaks to your decision. This is where the problems concentrate.
What is wrong with the human studies
| Aspect | What is typically seen | Why it matters |
|---|---|---|
| Sample size | Frequently fewer than thirty participants, sometimes fewer than fifteen | Small studies produce unstable results. A real but modest effect cannot be distinguished from chance, and an apparently large effect may not replicate. |
| Control group | Often absent, or compared against no treatment rather than against a placebo | Without a group receiving the delivery method plus a placebo, the effect of the needling and the effect of the preparation cannot be separated. |
| Blinding | Frequently absent or applied only to the participant | Assessors who know which treatment was given rate outcomes more favourably. Photographic assessment is particularly susceptible. |
| Outcome measures | Investigator and patient satisfaction scales, before and after photographs | Subjective measures move with expectation. Objective measures such as standardised imaging analysis or biopsy are used far less often. |
| Follow up | Commonly measured in weeks to three months | Both skin remodelling and the hair cycle operate over longer periods. Short follow up cannot establish durability, and cannot detect late adverse effects. |
| Funding and independence | Manufacturer involvement is common as funder, employer or product supplier | Industry funded work reports positive findings more often, and negative results are less likely to be published at all. |
| Product definition | Source, isolation method and characterisation often reported incompletely | If the product cannot be identified precisely, the result cannot be reproduced and cannot be applied to a different preparation. |
| Registration | Prospective registration of protocol and outcomes is often absent | Without it, outcome measures can be selected after the results are seen, which inflates apparent effectiveness. |
None of those weaknesses is unique to this field. Aesthetic medicine as a whole has a weak evidence culture, and small uncontrolled studies with satisfaction scores are common across it. What is specific here is the combination of all of them at once, together with a product category that is not standardised.
The comparability problem
This deserves its own section because it is the issue that makes the literature difficult to aggregate.
Two preparations both sold as exosomes may differ in every respect that matters. The source cells may be from different tissues, different species or plant material entirely. The isolation method may be centrifugation, filtration, chromatography or precipitation, and each yields a different mixture of vesicles and non vesicle material. The characterisation may be thorough or may amount to a particle count. Storage and reconstitution differ. Dose is expressed in units that do not convert into one another.
The consequence is that a well conducted study of preparation A tells you about preparation A. It does not transfer to preparation B, even though both will be described to you with the same word. When a clinic cites research to support the treatment they are offering, the useful question is whether that research used the product in the room.
Ask which studies support the specific preparation the clinic uses. Not exosomes in general. That preparation. Then ask whether the study had a control group and who funded it. The quality of the answer tells you more about the clinic than any amount of before and after photography.
Funding and publication
Much of the human clinical work in this area involves the companies that supply the preparations, either as funders, as employers of the authors, or as suppliers of free product. This is normal in early stage development and it is not by itself misconduct. It does have measurable effects, documented across medicine as a whole: industry funded studies report favourable results more often than independently funded studies of the same question, and studies with negative results are less likely to be submitted and less likely to be published.
The practical effect is that the published record in a young, commercially driven field is likely to be more positive than the underlying reality. That is an argument for waiting rather than for dismissing, and it is another reason why the absence of large independent trials matters.
What is missing
- Large randomised controlled trials with placebo comparison and blinded assessment, for any specific preparation, in any specific indication.
- Head to head comparison against the delivery method alone, which is the comparison that would settle the attribution question.
- Long term follow up. Most published follow up is measured in weeks to a few months. Durability of any effect is unknown.
- Standardised, objective outcome measures instead of investigator and patient satisfaction scales.
- Systematic adverse event collection. Rare harms are invisible without it, and small short studies cannot detect them.
- Any UK specific outcome data at all. No registry, no aggregate reporting, no appraisal.
- Product standardisation, without which none of the above can be pooled even if it existed.
What a reasonable person does with this
Not necessarily refuse the treatment. Early evidence is how every treatment starts, and people have always made decisions ahead of the data. But a decision made ahead of the data should be recognised as such.
The reasonable position is this. Understand that you are buying something whose effect size is unknown, delivered by a method that has an effect of its own, in a product category with no standardisation, outside the licensing framework. If that is acceptable to you at the price quoted, proceed with your eyes open. If a clinic has described it to you as proven, clinically validated or backed by science, they have described something that does not currently exist, and that is a reason to be more careful about everything else they tell you.
The consultation checklist turns this into twelve specific questions. The regulation page covers why the evidence position and the licensing position are the same problem viewed from two directions.
Common questions
Is there any good evidence for exosomes in aesthetics
There is a substantial and genuinely interesting body of laboratory science on extracellular vesicles as signalling particles. What there is not, at the time of writing, is a large independent randomised controlled trial of a specific exosome preparation for a specific aesthetic or hair indication, with a placebo control, blinded objective assessment and follow up long enough to matter. Those are different categories of evidence and only the second supports a promise to a patient.
Why does industry funding matter so much here
Funding does not make a result false. It does shift the odds, because studies funded by a company with an interest in the outcome report positive findings more often than independently funded studies of the same question, and because negative results are less likely to be published at all. In a field where most of the human work involves the supplier of the product, that publication pattern is a reason for caution rather than a reason for dismissal.
What would convince you
A randomised trial in which participants receive either microneedling plus the preparation or microneedling plus a matched placebo, allocated at random, assessed by someone blinded to the allocation, using objective measures rather than satisfaction scores, with follow up of at least six months, run independently of the manufacturer, with enough participants for the result to mean something, and pre registered so that the outcome measures cannot be chosen after the fact.
Why do studies of different products not add up
Because they are not studies of the same thing. Source cells differ, isolation methods differ, characterisation standards differ, storage differs and dose is measured in incompatible units. Adding the results together produces a number with no meaning. In a licensed medicine, the marketing authorisation is what guarantees that the product in the trial and the product in the vial are the same. That guarantee is absent here.
Is there UK data
No. There is no national registry collecting outcomes for these treatments, no professional body publishing aggregate results, and no NICE appraisal of exosome therapy for cosmetic indications. Where a UK figure is quoted to you, ask for its source, and expect it to be either a single clinic's own audit or a number with no origin at all.
This page contains no commercial links of any kind. No clinic, practitioner, product or supplier is named, recommended or linked to, and nobody has paid for, influenced or previewed anything on it. External links go only to UK regulators and professional bodies and carry a nofollow attribute. Published by Northbank Media under our editorial policy.
If you want to speak to someone
We are not a clinic and we give no medical advice. If you would like to, we can pass your details to a registered UK practitioner who will contact you directly. Nothing is booked on your behalf and there is no obligation. Read the regulation page first.
Make an enquiry